phrykt

Anaptysbio, Inc (ANAB): who owns it and who trades it

As of Nov 16, 2026, ANAB insiders reported 42 open-market sales worth $9.8M and no purchases in the last 12 months, with 37% of the sale value made under pre-set 10b5-1 plans. The largest seller was Daniel Faga (CEO), with $2.8M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Anaptysbio

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ANAB

211 funds and institutions reported ANAB shares worth $2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is EcoR1 Capital, LLC with 27.1%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

EcoR1 Capital, LLC27.1%
BlackRock, Inc.6.3%
Tang Capital Management LLC4.6%
State Street Corp4.4%
Vanguard Capital Management LLC3.1%
Affinity Asset Advisors, LLC2.8%
Sanofi2.8%
Millennium Management LLC2.8%
Woodline Partners LP2.5%
683 Capital Management, LLC2.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
EcoR1 Capital, LLC7.88M27.08%$532MNo change
BlackRock, Inc.1.84M6.34%$124M+10%
Tang Capital Management LLC1.33M4.57%$89.8MNo change
State Street Corp1.29M4.42%$86.8M+30%
Vanguard Capital Management LLC906,2333.11%$61.2M+6%
Affinity Asset Advisors, LLC826,1092.84%$55.8M-12%
Sanofi821,9172.82%$55.5MNo change
Millennium Management LLC807,3162.77%$54.5M+70%
Woodline Partners LP717,0142.46%$48.4M+108%
683 Capital Management, LLC660,0002.27%$44.6M+6%
Geode Capital Management, LLC637,8732.19%$43.1M+23%
Palo Alto Investors LP603,4892.07%$40.7M-5%
Goldman Sachs Group Inc584,0702.01%$39.4M+76%
First Light Asset Management, LLC582,0042.00%$39.3M+3%
D. E. Shaw & Co., Inc.539,6661.85%$36.4M-7%
Vanguard Portfolio Management LLC527,8581.81%$35.6M+2%
Apis Capital Advisors, LLC497,0001.71%$33.5M+109%
Sofinnova Investments, Inc.493,5361.70%$33.3M+99%
Arrowstreet Capital, Limited Partnership488,6511.68%$33M-1%
Nuveen, LLC420,6641.45%$28.4M+33%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ANAB insiders reported $0 of open-market purchases and $9.8M of sales. 37% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$9.8M
42 trades, 8 people
Sales under a 10b5-1 plan
37%
Share of sale value
Latest trade
Oct 1, 2026
Filed Oct 2, 2026

Purchases and sales by month

$3.7M$3.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 1, 2026Hollings RentonDirectorSale plan5,000$49.87$249KForm 4
Mar 30, 2026John P. SchmidDirectorSale12,596$55.71$702KForm 4
Mar 30, 2026John P. SchmidDirectorSale7,527$56.70$427KForm 4
Mar 30, 2026John P. SchmidDirectorSale522$57.40$30KForm 4
Mar 27, 2026Daniel FagaCEOSale100$65.99$6.6KForm 4
Mar 27, 2026Daniel FagaCEOSale3,038$65.20$198KForm 4
Mar 27, 2026Daniel FagaCEOSale3,155$64.19$203KForm 4
Mar 27, 2026Daniel FagaCEOSale2,592$63.35$164KForm 4
Mar 27, 2026Daniel FagaCEOSale1,012$62.15$62.9KForm 4
Mar 27, 2026Daniel FagaCEOSale550$60.63$33.3KForm 4
Mar 27, 2026Daniel FagaCEOSale490$59.62$29.2KForm 4
Mar 27, 2026Daniel FagaCEOSale3,662$58.62$215KForm 4
Mar 27, 2026Daniel FagaCEOSale510$56.61$28.9KForm 4
Mar 27, 2026Daniel FagaCEOSale2,570$57.91$149KForm 4
Feb 11, 2026Eric J LoumeauCHIEF LEGAL OFFICERSale plan10,000$54.00$540KForm 4
Jan 15, 2026Magda MarquetDirectorSale9,290$48.12$447KForm 4
Jan 15, 2026Magda MarquetDirectorSale1,710$48.85$83.5KForm 4
Jan 8, 2026Paul F. LizzulChief Medical OfficerSale3,650$44.71$163KForm 4
Jan 8, 2026Dennis MulroyCFOSale2,515$44.71$112KForm 4
Jan 8, 2026Eric J LoumeauCHIEF LEGAL OFFICERSale2,210$44.71$98.8KForm 4
Jan 8, 2026Daniel FagaCEOSale14,281$44.71$639KForm 4
Jan 7, 2026Eric J LoumeauCHIEF LEGAL OFFICERSale2,017$45.11$91KForm 4
Jan 7, 2026Eric J LoumeauCHIEF LEGAL OFFICERSale5,281$45.38$240KForm 4
Jan 7, 2026Eric J LoumeauCHIEF LEGAL OFFICERSale500$47.23$23.6KForm 4
Jan 7, 2026Eric J LoumeauCHIEF LEGAL OFFICERSale1,841$46.13$84.9KForm 4
Jan 7, 2026Paul F. LizzulChief Medical OfficerSale2,235$45.11$101KForm 4
Jan 7, 2026Daniel FagaCEOSale9,202$45.11$415KForm 4
Jan 7, 2026Dennis MulroyCFOSale1,908$45.11$86.1KForm 4
Jan 5, 2026Daniel FagaCEOSale15,309$43.26$662KForm 4
Jan 5, 2026Dennis MulroyCFOSale3,363$43.26$145KForm 4
Jan 5, 2026Paul F. LizzulChief Medical OfficerSale4,219$43.26$183KForm 4
Jan 5, 2026Eric J LoumeauCHIEF LEGAL OFFICERSale2,983$43.26$129KForm 4
Dec 23, 2025J. Anthony WareDirectorSale3,900$49.58$193KForm 4
Dec 22, 2025Paul F. LizzulChief Medical OfficerSale plan1,500$50.00$75KForm 4
Dec 22, 2025Dennis MulroyCFOSale plan10,000$50.00$500KForm 4
Dec 22, 2025Eric J LoumeauCHIEF LEGAL OFFICERSale plan10,000$51.00$510KForm 4
Dec 18, 2025Eric J LoumeauCHIEF LEGAL OFFICERSale plan141$46.99$6.6KForm 4
Dec 17, 2025Eric J LoumeauCHIEF LEGAL OFFICERSale plan10,000$46.00$460KForm 4
Dec 16, 2025Eric J LoumeauCHIEF LEGAL OFFICERSale plan8,305$44.68$371KForm 4
Dec 16, 2025Eric J LoumeauCHIEF LEGAL OFFICERSale plan4,195$45.24$190KForm 4
Dec 16, 2025Dennis MulroyCFOSale plan9,365$44.62$418KForm 4
Dec 16, 2025Dennis MulroyCFOSale plan6,360$45.21$288KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Daniel FagaPresident, CEO, Director–$2.8MMar 27, 2026
Eric J LoumeauCHIEF LEGAL OFFICER–$2.7MFeb 11, 2026
Dennis MulroyCHIEF FINANCIAL OFFICER–$1.5MJan 8, 2026
John P. SchmidDirector–$1.2MMar 30, 2026
Magda MarquetDirector–$531KJan 15, 2026
Paul F. LizzulChief Medical Officer–$522KJan 8, 2026
Hollings RentonDirector–$249KOct 1, 2026
J. Anthony WareDirector–$193KDec 23, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ANAB short interest

High short interest. 16.9% of ANAB shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 5%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.05M ANAB shares were sold short, 16.9% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 468,120 shares, buying them all back would take about 10.8 trading days (days to cover).

Shares short, % of all shares

16.9%May 15Oct 3019.1%

Days to cover

10.8May 15Oct 3017.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.05M16.89%-6%468,12010.8
Oct 15, 20265.39M18.04%+3%507,97210.6
Sep 30, 20265.24M17.51%-4%639,5248.2
Sep 15, 20265.44M18.68%+0%530,30610.2
Aug 31, 20265.41M18.60%+2%347,13515.6
Aug 14, 20265.32M18.27%-2%372,08914.3
Jul 31, 20265.40M18.56%+8%749,4007.2
Jul 15, 20265.00M17.18%-3%853,4965.9
Jun 30, 20265.15M17.69%+11%622,5148.3
Jun 15, 20264.63M15.92%-4%566,9288.2
May 29, 20264.82M16.57%+1%489,6779.8
May 15, 20264.80M16.48%+8%660,9587.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Anaptysbio company events

Anaptysbio filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Aug 11, 2026.

  1. Aug 11, 2026VoteReported shareholder vote results. Filing
  2. Jul 30, 2026AnnouncementShared information with investors. Filing
  3. Jun 22, 2026AgreementAnaptysBio, Inc., entered into a Sublease Agreement with First Tracks Biotherapeutics, Inc., a Delaware corporation, pursuant to which the Company agreed to sublease to First Tracks approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121. Filing
  4. May 29, 2026AnnouncementShared information with investors. Filing
  5. May 21, 2026RulesChanged its bylaws or articles. Filing
  6. May 12, 2026ResultsReleased financial results. Filing
  7. May 11, 2026LeadershipAnaptysBio, Inc. announced that its Board of Directors appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026. Filing
  8. Apr 20, 2026LeadershipBoard Departures In connection with the Spin-Off, each of Dennis Fenton, Rita Jain and Magda Marquet resigned from the board of directors of the Company, effective as of April 20, 2026, and J. Anthony Ware resigned from the board of directors of the Company, effective as of April 23, 2026. Filing
  9. Mar 27, 2026LeadershipThe Board appointed Susannah Gray as a Class I director, a member of the Nominating and Corporate Governance Committee and a member of the Research and Development Committee, effective immediately. Filing
  10. Mar 3, 2026ResultsReleased financial results. Filing
  11. Jan 9, 2026ResultsReleased financial results. Filing
  12. Nov 26, 2025AnnouncementShared information with investors. Filing
  13. Nov 21, 2025AnnouncementAnaptysBio, Inc. issued a press release announcing that its Board of Directors authorized an amendment to its Stock Repurchase Plan previously approved in March 2025, under which the Company may repurchase up to an additional $100.0 million of the Company’s outstanding common stock, par value… Filing
  14. Nov 21, 2025AnnouncementAnaptysBio, Inc. ( AnaptysBio ) filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. has materially breached the parties’ Collaboration and Exclusive License Agreement and that GlaxoSmithKline (“ GSK ” ), Tesaro’s corporate parent, has tortiously… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Anaptysbio financials

Famous investors that hold ANAB

4 of the 50 well-known investors we track reported holding ANAB in their latest 13F filing. The largest position is Israel Englander's, worth $39.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026784,560$39.4M0.0%-3%
Ken Griffin · Citadel AdvisorsQ3 2026650,585$32.7M0.0%+65%
Steve Cohen · Point72 Asset ManagementQ3 202627,218$1.4M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202623,436$1.2M0.0%+17%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ANAB in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Sirenia Capital Management LP13G/A3.1%
Nov 16, 2026Sirenia Capital Management LP13G/A3.1%

Questions about Anaptysbio, Inc (ANAB) stock

Who owns the most ANAB stock?

The largest reported owner of Anaptysbio, Inc (ANAB) is EcoR1 Capital, LLC, with 27.1% of the company. In total, 211 funds and institutions reported holding ANAB at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are ANAB insiders buying or selling?

In the last 12 months, ANAB insiders reported no open-market purchases and 42 sales worth $9.8M. The latest trade was on Oct 1, 2026. See every trade.

What is the short interest in ANAB?

As of Oct 30, 2026, 5.05M ANAB shares were sold short, 16.9% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 468,120 shares, buying them all back would take about 10.8 trading days (days to cover). See the history.

Which famous investors hold ANAB?

4 of the 50 well-known investors we track reported ANAB in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $39.4M. See all holders.

Executive pay

Anaptysbio's chief executive was paid a total of $6.1M for the year ended Dec 31, 2025, down 55% from $13.6M the year before. In the last 12 months, Anaptysbio's executives and directors bought no stock on the open market and sold $9.8M.

Chief executive, total pay$6.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$41.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.